| Literature DB >> 23169282 |
A Vrieling1, K Buck, P Seibold, J Heinz, N Obi, D Flesch-Janys, J Chang-Claude.
Abstract
BACKGROUND: Research on the association between dietary patterns and breast cancer survival is very limited.Entities:
Mesh:
Year: 2012 PMID: 23169282 PMCID: PMC3553521 DOI: 10.1038/bjc.2012.521
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Food group factor loadings for the ‘healthy’ and ‘unhealthy’ dietary pattern
|
|
|
|
|---|---|---|
| Potatoes | 0.01 | 0.27 |
| Vegetables |
| 0.09 |
| Legumes | 0.15 | 0.07 |
| Fruits |
| −0.11 |
| Dairy products | 0.10 | −0.05 |
| Pasta, rice, and other grain | 0.25 | −0.08 |
| Bread | −0.04 | 0.23 |
| Other cereals | 0.15 | −0.17 |
| Red meat | 0.12 |
|
| Processed meat | −0.02 |
|
| Poultry | 0.19 | 0.29 |
| Fish and shellfish | 0.18 | 0.04 |
| Eggs and egg products | −0.01 | 0.18 |
| Vegetable oils |
| 0.07 |
| Butter | −0.15 | 0.18 |
| Margarine | 0.02 | 0.16 |
| Deep-frying fat | 0.01 |
|
| Sugar and confectionery | −0.02 | 0.15 |
| Cakes | −0.01 | 0.11 |
| Non-alcoholic beverages | 0.20 | −0.03 |
| Wine | 0.05 | −0.04 |
| Other alcoholic beverages | −0.06 | 0.03 |
| Sauces and condiments |
| 0.16 |
| Soups and bouillons |
| 0.09 |
| Soy products | 0.09 | −0.10 |
Factor loadings ⩾0.30/⩽−0.30 are shown in bold.
HRs of overall mortality, breast cancer-specific mortality, and other mortality according to quartiles of dietary patterns in the MARIE study, Germany, 2001–2009
|
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||
|
| ||||||||||
| Q1 | 631 | 101 | 1.00 | 75 | 1.00 | 26 | 1.00 | |||
| Q2 | 630 | 68 | 0.71 | 0.52, 0.97 | 50 | 0.67 | 0.47, 0.96 | 18 | 0.84 | 0.45, 1.54 |
| Q3 | 631 | 74 | 0.77 | 0.56, 1.04 | 57 | 0.76 | 0.54, 1.09 | 17 | 0.77 | 0.41, 1.45 |
| Q4 | 630 | 73 | 0.77 | 0.56, 1.05 | 53 | 0.73 | 0.51, 1.05 | 20 | 0.89 | 0.49, 1.63 |
| | 0.06 | 0.04 | 0.80 | |||||||
|
| ||||||||||
| Q1 | 614 | 97 | 1.00 | 72 | 1.00 | 25 | 1.00 | |||
| Q2 | 616 | 62 | 0.77 | 0.55, 1.08 | 46 | 0.76 | 0.51, 1.14 | 16 | 0.81 | 0.41, 1.57 |
| Q3 | 617 | 72 | 0.81 | 0.58, 1.13 | 55 | 0.83 | 0.56, 1.23 | 17 | 0.82 | 0.42, 1.58 |
| Q4 | 609 | 68 | 0.87 | 0.61, 1.23 | 50 | 0.89 | 0.59, 1.35 | 18 | 0.81 | 0.40, 1.61 |
| | 0.20 | 0.25 | 0.66 | |||||||
|
| ||||||||||
|
| ||||||||||
| Q1 | 631 | 72 | 1.00 | 61 | 1.00 | 11 | 1.00 | |||
| Q2 | 630 | 69 | 0.95 | 0.68, 1.32 | 48 | 0.77 | 0.52, 1.13 | 21 | 1.96 | 0.93, 4.12 |
| Q3 | 631 | 76 | 1.06 | 0.76, 1.47 | 60 | 1.00 | 0.69, 1.43 | 16 | 1.42 | 0.65, 3.08 |
| Q4 | 630 | 99 | 1.39 | 1.02. 1.89 | 66 | 1.06 | 0.74, 1.50 | 33 | 3.41 | 1.69, 6.85 |
| | 0.01 | 0.44 | <0.001 | |||||||
|
| ||||||||||
| Q1 | 619 | 69 | 1.00 | 59 | 1.00 | 10 | 1.00 | |||
| Q2 | 615 | 67 | 1.03 | 0.72, 1.47 | 46 | 0.88 | 0.58, 1.33 | 21 | 2.06 | 0.94, 4.54 |
| Q3 | 611 | 72 | 1.11 | 0.77, 1.59 | 58 | 1.07 | 0.71, 1.61 | 14 | 1.46 | 0.63, 3.39 |
| Q4 | 611 | 91 | 1.34 | 0.93, 1.94 | 60 | 0.99 | 0.64, 1.52 | 31 | 3.69 | 1.66, 8.17 |
| | 0.03 | 0.59 | <0.001 | |||||||
Abbreviations: CI=confidence interval; ERPR=oestrogen receptor/progesterone receptor; HR=hazard ratio; HRT=hormone replacement therapy; Q=quartile.
The model was stratified by age at diagnosis and study centre.
The model was stratified by age at diagnosis and study centre, and adjusted for tumour size, nodal status, metastases, tumour grade, ERPR status, radiotherapy, HRT use at diagnosis, mode of detection, and total energy intake; the model for other mortality was additionally adjusted for cardiovascular disease; because of missing covariate values, 66 observations were not included in model 2. Other potentially confounding variables, as specified in Supplementary Table 1, were not statistically significant and did not change the risk estimates by ⩾10% when tested in the model and were therefore not included in the final model.
HRs of recurrence among stage I–IIIa breast cancer patients according to quartiles of dietary patterns in the MARIE study, Germany, 2001–2009
|
| ||||
|---|---|---|---|---|
|
|
|
|
|
|
|
| ||||
|
| ||||
| Q1 | 527 | 69 | 1.00 | |
| Q2 | 554 | 58 | 0.82 | 0.58, 1.17 |
| Q3 | 553 | 62 | 0.82 | 0.57, 1.16 |
| Q4 | 550 | 58 | 0.84 | 0.59, 1.21 |
| | 0.11 | |||
| | ||||
|
| ||||
| Q1 | 517 | 67 | 1.00 | |
| Q2 | 542 | 56 | 0.84 | 0.58, 1.21 |
| Q3 | 543 | 61 | 0.77 | 0.54, 1.12 |
| Q4 | 533 | 55 | 0.71 | 0.48, 1.06 |
| | 0.02 | |||
|
| ||||
|
| ||||
| Q1 | 557 | 60 | 1.00 | |
| Q2 | 549 | 61 | 1.02 | 0.71, 1.46 |
| Q3 | 539 | 52 | 0.88 | 0.60, 1.28 |
| Q4 | 539 | 74 | 1.20 | 0.85, 1.70 |
| | 0.32 | |||
| | ||||
|
| ||||
| Q1 | 546 | 59 | 1.00 | |
| Q2 | 538 | 60 | 0.99 | 0.68, 1.44 |
| Q3 | 527 | 52 | 0.76 | 0.51, 1.13 |
| Q4 | 524 | 68 | 0.91 | 0.61, 1.36 |
| | 0.72 | |||
Abbreviations: CI=confidence interval; ERPR=oestrogen receptor/progesterone receptor; HR=hazard ratio; HRT=hormone replacement therapy; Q=quartile.
The model was stratified by age at diagnosis and study centre.
The model was stratified by age at diagnosis and study centre, and adjusted for tumour size, nodal status, metastases, tumour grade, ERPR status, radiotherapy, HRT use at diagnosis, mode of detection, and total energy intake; because of missing covariate values, 49 observations were not included in model 2. Other potentially confounding variables, as specified in Supplementary Table 1, were not statistically significant and did not change the risk estimates by ⩾10% when tested in the model and were therefore not included in the final model.